Affiliation: University of Washington
- Understanding, treating and avoiding hematological disease: better medicine through mathematics?David C Dale
Department of Medicine, University of Washington, Seattle, WA, 98195, USA
Bull Math Biol 77:739-57. 2015..It's also a story of their efforts to offer effective treatments for the patients who suffer from cyclic neutropenia and other conditions causing neutropenia and infections...
- Mutations in the gene encoding neutrophil elastase in congenital and cyclic neutropeniaD C Dale
Divisions of Hematology and Medical Genetics, Department of Medicine and the Markey Molecular Medicine Center, University of Washington School of Medicine, Seattle, WA, USA
Blood 96:2317-22. 2000..This study indicates that mutations of the gene encoding neutrophil elastase are probably the most common cause for severe congenital neutropenia as well as the cause for sporadic and autosomal dominant cyclic neutropenia...
- Optimizing the management of chemotherapy-induced neutropeniaDavid C Dale
Department of Medicine, University of Washington, Seattle, WA 98195, USA
Clin Adv Hematol Oncol 1:679-84. 2003..The availability of pegfilgrastim, a sustained-duration G-CSF that has benefits comparable to those of filgrastim with a single injection per chemotherapy cycle, has simplified CSF therapy...
- Poor prognosis in elderly patients with cancer: the role of bias and undertreatmentDavid C Dale
University of Washington, Seattle, Washington 98195, USA
J Support Oncol 1:11-7. 2003..Establishing age-based standards for cancer care will become more important as the US population ages...
- Recertification in internal medicine - the American experienceDavid C Dale
American College of Physicians, Seattle, WA, USA
Ann Acad Med Singapore 36:894-7. 2007..MOC has been well received by professional organisations, but there are areas of controversy. It has been accepted as an important way for internists to assure quality of practice and currency of medical information...
- The phagocytes: neutrophils and monocytesDavid C Dale
Department of Medicine, University of Washington School of Medicine, Seattle A98195, USA
Blood 112:935-45. 2008..Over the last 50 years, many genetic and molecular disorders of phagocytes have been identified, leading to improved diagnosis and treatment of conditions which predispose patients to the risk of recurrent fevers and infectious diseases...
- Neutrophil biology and the next generation of myeloid growth factorsDavid C Dale
Department of Medicine, University of Washington, Seattle, WA 98195 6422, USA
J Natl Compr Canc Netw 7:92-8. 2009..Advances in neutrophil biology coupled with better understanding and development of myeloid growth factors offer great promise for improving the care of patients with cancer and many other disorders...
- Advances in the treatment of neutropeniaDavid C Dale
Department of Medicine, University of Washington School of Medicine, Seattle, Washington 98195, USA
Curr Opin Support Palliat Care 3:207-12. 2009..The present review updates treatment of neutropenia from articles published from January 2008 through April 2009...
- Mobilization of hematopoietic progenitor cells in healthy volunteers by AMD3100, a CXCR4 antagonistW Conrad Liles
Department of Medicine, University of Washington, HSB AA 522, Box 356422, Seattle, WA 98195
Blood 102:2728-30. 2003..AMD3100 was well tolerated and caused only mild, transient toxicity. These findings suggest potential clinical application of AMD3100 for CD34+ cell mobilization and collection for hematopoietic stem cell transplantation...
- Alpha Omega Alpha: encouraging excellence in medicine for more than a centuryDavid C Dale
Alpha Omega Alpha, 525 Middlefield Road, Suite 130, Menlo Park, California 94025, USA
Pharos Alpha Omega Alpha Honor Med Soc 65:4-21. 2002
- Severe chronic neutropenia: treatment and follow-up of patients in the Severe Chronic Neutropenia International RegistryDavid C Dale
Department of Medicine, Box 356422, University of Washington, Seattle, WA 98195, USA
Am J Hematol 72:82-93. 2003..The risk of leukemia, osteoporosis, other potentially adverse events, and pregnancy outcome need to be further evaluated with continuing long-term observations...
- Colony-stimulating factors for the management of neutropenia in cancer patientsDavid C Dale
Department of Medicine, University of Washington, Seattle, Washington 98195 6422, USA
Drugs 62:1-15. 2002....
- Myelotoxicity and dose intensity of chemotherapy: reporting practices from randomized clinical trialsDavid C Dale
University of Washington, Department of Medicine, Box 356422, HSB, Room AA522, 1959 NE Pacific, Seattle, WA 98195 6422, USA
J Natl Compr Canc Netw 1:440-54. 2003..We recommend that standard procedures for documenting and reporting hematologic toxicity and dose intensity in cancer chemotherapy trials be required for publication of chemotherapy trials...
- Cyclic and chronic neutropeniaDavid C Dale
Department of Medicine, University of Washington, Seattle, WA 98195, USA
Cancer Treat Res 157:97-108. 2011..Ten to thirty percent of severe congenital neutropenia patients evolve to develop acute myeloid leukemia, necessitating careful clinical monitoring...
- Current management of chemotherapy-induced neutropenia: the role of colony-stimulating factorsDavid Dale
Department of Medicine, University of Washington, 1959 NE Pacific St, Box 356422, Seattle, WA 98195, USA
Semin Oncol 30:3-9. 2003..This review summarizes the clinical consequences of CIN and describes current best practices for the management of patients at risk for CIN...
- Treatment of canine cyclic neutropenia by lentivirus-mediated G-CSF deliveryOfer Yanay
Department of Pediatrics, MS 356320, University of Washington, Seattle, WA 98195, USA
Blood 102:2046-52. 2003..Thus, intramuscular administration of lentivirus encoding G-CSF provided sustained therapeutic levels of neutrophils, suggesting this approach may be applied for long-term treatment of patients with cyclic and other neutropenias...
- Cellular and molecular abnormalities in severe congenital neutropenia predisposing to leukemiaAndrew A G Aprikyan
Department of Medicine, University of Washington School of Medicine, Seattle, Wash, USA
Exp Hematol 31:372-81. 2003..Furthermore, our results suggest that acquired G-CSFR mutations may initiate signaling events that override the pro-apoptotic effect of mutant NE in primitive progenitor cells, resulting in an expansion of the abnormal AML clone...
- Cloning and sequencing of the canine neutrophil elastase cDNALouis J Katen
Division of Pediatric Genetics, Department of Pediatrics, HSB RR244 Box 356320, University of Washington School of Medicine, 1959 NE Pacific St, Seattle, WA 98195, USA
DNA Seq 13:221-3. 2002..Towards the validation of this animal model, we have cloned and sequenced the canine NE cDNA from a normal dog...
- Molecular basis and therapy of disorders associated with chronic neutropeniaSteven M Stein
Department of Medicine, University of Washington School of Medicine, 1959 NE Pacific Street, Box 356422, Seattle, WA 98195, USA
Curr Allergy Asthma Rep 3:385-8. 2003..Granulocyte colony stimulating factor (G-CSF) is effective treatment for several of these conditions. Through better understanding of these disorders, we anticipate that better treatments will be found in the future...
- Mutant elastase in pathogenesis of cyclic and severe congenital neutropeniaAndrew A G Aprikyan
Department of Medicine, University of Washington, 1959 NE Pacific Street, Seattle, WA 98195 6422, USA
J Pediatr Hematol Oncol 24:784-6. 2002..We hypothesize that abnormal processing and subcellular localization of mutant NE might predetermine the etiology of cyclic or severe congenital neutropenia...
- Therapeutic use of cytokines to modulate phagocyte function for the treatment of infectious diseases: current status of granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor, macrophage colony-stimulating factor, and inteKai Hubel
Department of Medicine, University of Washington, Seattle, Washington, USA and Department I of Internal Medicine, University of Cologne, Cologne, Germany
J Infect Dis 185:1490-501. 2002..However, variable therapeutic efficacy has been reported in clinical trials conducted to date. This review summarizes the current status of the use of G-CSF, GM-CSF, M-CSF, and IFN-gamma in the treatment of infectious diseases...
- Augmented mobilization and collection of CD34+ hematopoietic cells from normal human volunteers stimulated with granulocyte-colony-stimulating factor by single-dose administration of AMD3100, a CXCR4 antagonistW Conrad Liles
Department of Medicine, University of Washington, Seattle, Washington 98195, USA
Transfusion 45:295-300. 2005..AMD3100, a selective antagonist of CXCR4, rapidly mobilizes CD34+ hematopoietic progenitor cells (HPCs) from marrow to peripheral blood with minimal side effects...
- Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapyMichelle Shayne
Department of Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York, USA
Cancer 110:1611-20. 2007..This prospective study was undertaken to evaluate patient and treatment characteristics that contribute to hematologic toxicity in older cancer patients...
- Updated ASCO recommendations for the use of white blood cell growth factorsDavid C Dale
University of Washington Medical Center, Seattle, WA 98195, USA
Clin Adv Hematol Oncol 4:664-6. 2006
- Introduction: severe chronic neutropeniaDavid C Dale
Department of Medicine, University of Washington, Seattle, WA 98195 6422, USA
Semin Hematol 39:73-4. 2002
- Cyclic neutropeniaDavid C Dale
Department of Medicine, and the Severe Chronic Neutropenia International Registry, University of Washington, Seattle, WA 98195 6422, USA
Semin Hematol 39:89-94. 2002..Leukemic transformation is not a recognized risk for cyclic neutropenia, with or without treatment with G-CSF...
- Prevalence of mutations in ELANE, GFI1, HAX1, SBDS, WAS and G6PC3 in patients with severe congenital neutropeniaJun Xia
Division of Oncology, Department of Medicine, Washington University School of Medicine, St Louis, MO 63110, USA
Br J Haematol 147:535-42. 2009..In patients without ELANE mutations, other known SCN-associated gene mutations will be found rarely and genotyping can be guided by the clinical features of each patient...
- An adult dog with cyclic neutropenia treated by lentivirus- mediated delivery of granulocyte colony-stimulating factorOfer Yanay
Department of Pediatrics, University of Washington, Seattle, WA 98195, USA
Hum Gene Ther 17:464-9. 2006..These studies show that an adult animal is responsive long-term to lentivirus-mediated G-CSF delivery, suggesting this approach may be applied for treatment of adult patients with cyclic and other neutropenias...
- Effective storage of granulocytes collected by centrifugation leukapheresis from donors stimulated with granulocyte-colony-stimulating factorKai Hubel
Department of Medicine, University of Washington, WA 98195 8050, USA
Transfusion 45:1876-89. 2005..10 degrees C) with maintenance of functional properties in vitro and in vivo...
- Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapyMichelle Shayne
Department of Medicine, University of Rochester and the James P Wilmot Cancer Center, Rochester, NY, USA
Cancer 115:5319-28. 2009..This prospective study evaluated patient and treatment characteristics that contributed to hematologic toxicity in older breast cancer patients treated with curative intent in the community setting...
- Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropeniaDaniel C Link
Division of Oncology, Department of Medicine, Washington University, St Louis, MO 63110, USA
Blood 110:1648-55. 2007..These data support the hypothesis that mutations of CSF3R may provide the "activated tyrosine kinase signal" that is thought to be important for leukemogenesis...
- Neutropenia: causes and consequencesLaurence Boxer
Department of Pediatrics, University of Washington, Seattle, WA 98195 6422, USA
Semin Hematol 39:75-81. 2002..Most severely neutropenic patients have a history of oral ulcers and inflammation and recurrent skin infections. Examination of a bone marrow aspirate and/or biopsy and cytogenetic testing are primary for diagnostic evaluation...
- Granulocyte transfusion therapy for infections in candidates and recipients of HPC transplantation: a comparative analysis of feasibility and outcome for community donors versus related donorsKai Hubel
Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA
Transfusion 42:1414-21. 2002....
- Effect of patient socioeconomic status and body mass index on the quality of breast cancer adjuvant chemotherapyJennifer J Griggs
Department of Medicine, University of Rochester, Rochester, NY, USA
J Clin Oncol 25:277-84. 2007..The purpose of this study was to investigate the relationship between socioeconomic status (SES) and the use of intentionally reduced doses of chemotherapy in the adjuvant treatment of breast cancer...
- Neutrophil elastase mutations and risk of leukaemia in severe congenital neutropeniaPhilip S Rosenberg
Biostatistics Branch, Division of Cancer Epidemiology and Genetics, Department of Health and Human Services, National Cancer Institute, National Institutes of Health, Rockville, MD, USA
Br J Haematol 140:210-3. 2008..96). Patients with either mutant or wild-type ELA2 should be followed closely for leukaemic transformation...
- Myeloid growth factors clinical practice guidelines in oncologyJeffrey Crawford
Duke Comprehensive Cancer Center, Duke University, Durham, NC, USA
J Natl Compr Canc Netw 3:540-55. 2005
- Predictors of chemotherapy-induced neutropenia and its complications: results from a prospective nationwide registryDebra Wolff
J Support Oncol 3:24-5. 2005
- The incidence of leukemia and mortality from sepsis in patients with severe congenital neutropenia receiving long-term G-CSF therapyPhilip S Rosenberg
Biostatistics Branch, Division of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, MD 20852 7244, USA
Blood 107:4628-35. 2006..Risk of MDS/AML may be similar in SDS and SCN. In less-responsive SCN patients, early hematopoietic stem cell transplantation may be a rational option...
- Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patientsNicole M Kuderer
James P Wilmot Cancer Center and Department of Medicine, University of Rochester, Rochester, New York 14642, USA
Cancer 106:2258-66. 2006..The study was undertaken to better define mortality, length of stay (LOS), cost, and risk factors associated with mortality and prolonged hospitalization in cancer patients with FN...
- Neutrophil elastase and granulocyte colony-stimulating factor receptor mutation analyses and leukemia evolution in severe congenital neutropenia patients belonging to the original Kostmann family in northern SwedenGoran Carlsson
Department of Woman and Child Health, Karolinska University Hospital Solna, Stockholm, Sweden
Haematologica 91:589-95. 2006..Mutations in the neutrophil elastase gene (ELA-2) have previously been identified in patients with sporadic or autosomal dominant SCN...
- Chemotherapy-induced neutropenia: risks, consequences, and new directions for its managementJeffrey Crawford
Divisions of Oncology and Hematology, Duke University Medical Center, PO Box 25178 Morris Building, Durham, NC 27710 0001, USA
Cancer 100:228-37. 2004..Research in quantifying the risk of neutropenic complications may make it possible in the near future to target patients at greater risk with appropriate preventive strategies, thereby maximizing the benefits and minimizing the costs...
- Kostmann syndrome: severe congenital neutropenia associated with defective expression of Bcl-2, constitutive mitochondrial release of cytochrome c, and excessive apoptosis of myeloid progenitor cellsGoran Carlsson
Childhood Cancer Research Center, Department of Woman and Child Health, Karolinska Hospital, Stockholm, Sweden
Blood 103:3355-61. 2004..In sum, these studies establish a role for mitochondria-dependent apoptosis in the pathogenesis of Kostmann syndrome and yield a tentative explanation for the beneficial effect of growth factor administration in these patients...
- Risk and timing of neutropenic events in adult cancer patients receiving chemotherapy: the results of a prospective nationwide study of oncology practiceJeffrey Crawford
Duke University, Durham, North Carolina, USA
J Natl Compr Canc Netw 6:109-18. 2008..Despite frequent planned reductions from standard RDI, the incidence of FN remains high in community oncology practice in the United States. Improved methods of pretreatment assessment of patient risk factors for neutropenia are needed...
- Risk of febrile neutropenia among patients with intermediate-grade non-Hodgkin's lymphoma receiving CHOP chemotherapyGary H Lyman
James P Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Avenue, Box 704 Rochester, NY 14642, USA
Leuk Lymphoma 44:2069-76. 2003..13, 95% CI: 1.20-3.76). Such a model may permit the identification of patients at greatest risk of febrile neutropenia and, therefore, candidates for the selective prophylactic use of the hematopoietic growth factors...
- Advances in the use of colony-stimulating factors for chemotherapy-induced neutropeniaDavid C Dale
J Support Oncol 3:39-41. 2005
- Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic reviewNicole M Kuderer
University of Rochester School of Medicine and Dentistry, James P Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA
J Clin Oncol 25:3158-67. 2007..Several RCTs have been published recently that investigate the impact of G-CSF on mortality and relative dose-intensity (RDI)...
- Predictors of reduced dose intensity in patients with early-stage breast cancer receiving adjuvant chemotherapyMichelle Shayne
James P Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Avenue, Box 704, Rochester, NY 14642, USA
Breast Cancer Res Treat 100:255-62. 2006..This retrospective study was undertaken to define risk factors for reductions in dose intensity of adjuvant chemotherapy in women with early stage breast cancer (ESBC)...
- Myeloid growth factors. Clinical practice guidelines in oncologyJeffrey Crawford
J Natl Compr Canc Netw 5:188-202. 2007
- Update on the management of neutropeniaDavid C Dale
Clin Adv Hematol Oncol 4:187-9. 2006
- Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonistHal E Broxmeyer
Department of Microbiology and Immunology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
J Exp Med 201:1307-18. 2005..These results support the hypothesis that the CXCL12-CXCR4 axis is involved in marrow retention of HSCs and HPCs, and demonstrate the clinical potential of AMD3100 for HSC mobilization...
- Severe congenital neutropeniaKarl Welte
Department of Pediatric Hematology Oncology, Medical School Hannover, Hannover, Germany
Semin Hematol 43:189-95. 2006..Hematopoietic stem cell transplantation (HSCT) is still the only treatment available for patients who are refractory to G-CSF treatment...
- Strong evidence for autosomal dominant inheritance of severe congenital neutropenia associated with ELA2 mutationsLaurence A Boxer
Divison of Pediatric Hematology Oncology, Department of Pediatrics, C S Mott Children s Hospital, University of Michigan, Ann Arbor, Michigan 48109 0238, USA
J Pediatr 148:633-6. 2006..To investigate cases of severe congenital neutropenia (SCN) to ascertain SCN inheritance after determining that the same sperm donor was used by 4 different families to impregnate mothers...
- Achieving a high-performance health care system with universal access: what the United States can learn from other countriesJack A Ginsburg
Ann Intern Med 148:55-75. 2008..This caution notwithstanding, we have identified several approaches that have worked well for countries like ours and could probably be adapted to the unique circumstances in the United States...
- Social and racial differences in selection of breast cancer adjuvant chemotherapy regimensJennifer J Griggs
University of Rochester, Rochester, NY, USA
J Clin Oncol 25:2522-7. 2007..Breast cancer outcomes are worse among black women and women of lower socioeconomic status. The purpose of this study was to investigate racial and social differences in selection of breast cancer adjuvant chemotherapy regimens...
- Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practicesGary H Lyman
James P Wilmot Cancer Center, University of Rochester Medical Center, 601 Elmwood Ave, Rochester, NY 14642, USA
J Clin Oncol 21:4524-31. 2003..This retrospective study was undertaken to assess practice patterns in adjuvant chemotherapy for early-stage breast cancer (ESBC) and to define the incidence and predictive factors of reduced relative dose-intensity (RDI)...
- Lineage-specific hematopoietic growth factorsDavid C Dale
N Engl J Med 355:526-7; author reply 527. 2006
- Epoetin alfa increases hemoglobin levels and improves quality of life in anemic geriatric cancer patients receiving chemotherapyMatti S Aapro
Clinique de Genolier, Genolier, Switzerland
Support Care Cancer 14:1184-94. 2006....
- MARROW REGULATION IN CYCLIC HEMATOPOIESISDavid Dale; Fiscal Year: 2003....